|Bid||3,184.00 x 6500|
|Ask||3,184.00 x 5600|
|Day's Range||3,161.00 - 3,190.00|
|52 Week Range||2,574.00 - 3,783.00|
|Beta (3Y Monthly)||1.26|
|PE Ratio (TTM)||14.82|
|Forward Dividend & Yield||0.85 (2.69%)|
|1y Target Est||N/A|
-- System improves mine health and safety by providing clean air for workers, with no impact on productivity. -- More than 99% of particulates are destroyed, giving the best possible work environment. AUDUBON, Pa., April 30, 2019 /PRNewswire/ --Johnson Matthey (JMAT.L), a global leader in science that enables a cleaner and healthier world, introduces an advanced system to control emissions from diesel underground mining equipment for healthier work environments.
Immunomedics, Inc., (IMMU) and Johnson Matthey (LSE: JMAT), today announced the companies have expanded their long-term master supply agreement under which Johnson Matthey will continue to scale the manufacturing of CL2A-SN-38, the drug-linker that is a key component of sacituzumab govitecan, Immunomedics’ lead antibody-drug conjugate currently under priority review by the FDA for accelerated approval as a treatment for patients with metastatic triple-negative breast cancer. This is part of Immunomedics' ongoing commitment to invest in and scale its global supply capacity with world-class partners in each component of its supply-chain.